RAS mutations are the most commonly found oncogenic alteration in human cancers, most frequently observed in KRAS (85%), and to a lesser degree in NRAS (12%) and HRAS (3%) (Simanshu et al., 2017). The gene discussed is HRAS; the disease is cancer.